On a CureTalks conversation earlier today with Dr. Carl June of the University of Pennsylvania (UPenn), we learned that his team had very recently treated two men with metastatic, castration-resistant prostate cancer (mCRPC) using chimeric antibody receptor T-cell therapy (CAR-T). … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: antibody, CAR-T, chimeric, receptor, T-cell | 9 Comments »
Immune checkpoint inhibitors include drugs like ipilimumab (Yervoy), pembrolizumab (Keytruda), nivolumab (Opdivo), and others that can have dramatic effects on the survival of some groups of patients with advanced forms of some cancers. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: antibody, checkpoint, immune, inhibitor, outcome, test, trial | 4 Comments »
A paper just published in Clinical Cancer Research has suggested that — at least for one immunotherapeutic agent (“vaccine”) in development for the treatment of advanced prostate cancer — it may be possible to define a subgroup of men who are more likely to respond well to treatment than others. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: antibody, glycan, microarray, PROSTVAC-VF, serum | 4 Comments »
With the exception of a paper on baseline erectile dysfunction in patients undergoing radical prostatectomy, today’s news reports are filled with esoterica that are likely to be of interest only to researchers and the truly obsessed patient! We have provided only very brief summaries of the articles and links to the original abstracts. … READ MORE …
Filed under: Diagnosis, Drugs in development, Management, Prevention, Treatment, Uncategorized | Tagged: antibody, biopsy, lymph node imaging, radiotherapy | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 